3-D Matrix Ltd. logo

3-D Matrix Ltd. (7777)

Market Closed
15 Jun, 06:00
JPX JPX
¥
341. 00
-18
-5.0139%
¥
9.76B Market Cap
- P/E Ratio
- Div Yield
8.45M Volume
- Eps
¥ 359
Previous Close
Add Transaction
Day Range
321 359
Year Range
176 793
Want to track 7777 and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!

Summary

7777 closed today lower at ¥341, a decrease of -5.0139% from yesterday's close, completing a monthly decrease of -19.9531% or -¥85. Over the past 12 months, 7777 stock lost -6.8306%.
7777 is not paying dividends to its shareholders.
The last earnings report, released on Mar 13, 2026, exceeded the consensus estimates by 0%. On average, the company has surpassed earnings expectations by 0%, based on the last three reports.
3-D Matrix Ltd. has completed 2 stock splits, with the recent split occurring on May 29, 2013.
The company's stock is traded on 2 different exchanges and in various currencies, with the primary listing on JPX (JPY).

7777 Chart

People also search for

Chordia Therapeutics Inc.
¥ 90
-7.2165%
Tsubota Laboratory Inc.
¥ 223
+1.8265%
Hyuga Primary Care Co., Ltd.
¥ 1,031
-0.5786%
Kyowakogyosyo Co. Ltd.
¥ 6,950
-0.8559%
A-One Seimitsu Inc.
¥ 2,002
+0.1%

3-D Matrix Ltd. (7777) FAQ

What is the stock price today?

The current price is ¥341.00.

On which exchange is it traded?

3-D Matrix Ltd. is listed on JPX.

What is its stock symbol?

The ticker symbol is 7777.

Does it pay dividends? What is the current yield?

It does not pay dividends to its shareholders.

What is its market cap?

As of today, the market cap is 9.76B.

Has 3-D Matrix Ltd. ever had a stock split?

3-D Matrix Ltd. had 2 splits and the recent split was on May 29, 2013.

3-D Matrix Ltd. Profile

Health Care Equipment & Supplies Industry
Healthcare Sector
Keiji Nagano CEO
JPX Exchange
JP3410730000 ISIN
JP Country
106 Employees
- Last Dividend
29 May 2013 Last Split
- IPO Date

Overview

3-D Matrix, Ltd. is a pioneering company that operates both within Japan and internationally, with a focus on the development of self-assembling peptide technology. This innovative technology finds extensive application in the burgeoning field of regenerative medicine, along with cell therapy, drug delivery systems, and various other industries. Since its inception in 2004, the company has established its headquarters in Tokyo, Japan, positioning itself as a key player in the development of advanced biomaterials.

Products and Services

PuraMatrix: The flagship product of 3-D Matrix, Ltd., PuraMatrix, is at the forefront of their offerings. It is a self-assembling peptide hydrogel that represents a significant advancement in the field of bioengineering and biomaterials. The applications of PuraMatrix are diverse and impactful:

  • Regenerative Medicine: In regenerative medicine, PuraMatrix provides a scaffold that facilitates the growth of new tissues by mimicking the body's natural extracellular matrix, thereby aiding in the healing and regrowth of damaged tissues.
  • Cell Therapy: For cell therapy, PuraMatrix serves as a delivery vehicle that supports the delivery and growth of therapeutic cells within the body. This application is critical in treatments that involve the restoration of cell function in damaged or diseased tissues.
  • Drug Delivery Systems: In drug delivery systems, PuraMatrix offers a unique medium for the controlled release of drugs, enabling targeted therapy with reduced side effects. This application capitalizes on the hydrogel's ability to encapsulate drugs and release them at a controlled rate.

Across these applications, PuraMatrix exemplifies the versatile and transformative potential of self-assembling peptide hydrogels in medicine, showcasing the innovative approach of 3-D Matrix, Ltd. towards solving complex biomedical challenges.

Contact Information

Address: Kojimachi HF Building
Phone: 81 3 3511 3440